Home > Insider Trading > Filing (0001144204-14-001695)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1138776	Medgenics Inc.	MDGN	Biological Products, (No Disgnostic Substances) (2836)	980217544

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1516544	Andrew Pearlman	C/O Medgenics, Inc. 435 Devon Park Drive Bldg 700 Wayne PA 19087		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-01-08	45,534	$2.49	86,096	No	4	M	Direct
Common Stock	Disposition	2014-01-08	45,534	$6.54	40,562	No	4	S	Direct
Common Stock	Acquisiton	2014-01-09	28,466	$2.49	69,028	No	4	M	Direct
Common Stock	Acquisiton	2014-01-09	6,000	$3.14	75,028	No	4	M	Direct
Common Stock	Disposition	2014-01-09	34,466	$6.69	40,562	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option Award	Disposition	2014-01-08	45,534	$0.00	45,534	$2.49
Common Stock	Option Award	Disposition	2014-01-09	28,466	$0.00	28,466	$2.49
Common Stock	Option Award	Disposition	2014-01-09	6,000	$0.00	6,000	$3.14

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
137,272	2014-09-13	No	4	M	Direct
108,806	2014-09-13	No	4	M	Direct
74,000	2021-12-09	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	94	Indirect	By Spouse
Common Stock	1,719	Indirect	By ADP Holdings LLC

Footnotes

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.47 to $6.82, inclusive. The reporting person undertakes to provide Medgenics, Inc., any security holder of Medgenics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.75, inclusive. The reporting person undertakes to provide Medgenics, Inc., any security holder of Medgenics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option award became exercisable in four equal annual installments beginning on March 31, 2007, which was the first anniversary of the grant date.
The expiration date of these options was previously reported as March 31, 2016.
The option award becomes exercisable in four equal annual installments beginning on December 9, 2012, which was the first anniversary of the grant date.